Revance Therapeutics Accepts Crown Increased Takeover Bid

Dow Jones

2025/01/21

By Colin Kellaher

Revance Therapeutics has accepted a sweetened bid from Crown Laboratories that raises the purchase price to $3.65 a share from $3.10.

Revance on Tuesday said it signed a revised merger agreement with privately held Crown, which has extended its tender offer for the Nashville, Tenn., biotechnology company to Feb. 4.

Crown raised its offer for Revance after Swiss medical-aesthetics company Teoxane, a key Revance customer, stepped in with a bid of $3.60 a share.

Crown last year agreed to buy Revance for $6.66 a share but later reduced the purchase price in part due to new agreements that Revance reached with Teoxane to resolve claims that Revance has breached a 2020 distribution agreement.

Revance shares closed Friday at $3.68, an indication that some investors might be expecting a bidding war for the company. The shares slipped 0.9% to $3.65 in premarket trading Tuesday.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 21, 2025 08:36 ET (13:36 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2505730302"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505730302\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2505730302?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-21 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505730302","market":"nz","top_or_hot":-1,"title":"Revance Therapeutics Accepts Crown Increased Takeover Bid","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Revance <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> has accepted a sweetened bid from Crown Laboratories that raises the purchase price to $3.65 a share from $3.10. \n</p>\n<p>\n  Revance on Tuesday said it signed a revised merger agreement with privately held Crown, which has extended its tender offer for the Nashville, Tenn., biotechnology company to Feb. 4. \n</p>\n<p>\n  Crown raised its offer for Revance after Swiss medical-aesthetics company Teoxane, a key Revance customer, stepped in with a bid of $3.60 a share. \n</p>\n<p>\n  Crown last year agreed to buy Revance for $6.66 a share but later reduced the purchase price in part due to new agreements that Revance reached with Teoxane to resolve claims that Revance has breached a 2020 distribution agreement. \n</p>\n<p>\n  Revance shares closed Friday at $3.68, an indication that some investors might be expecting a bidding war for the company. The shares slipped 0.9% to $3.65 in premarket trading Tuesday. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 21, 2025 08:36 ET (13:36 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revance Therapeutics Accepts Crown Increased Takeover Bid</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevance Therapeutics Accepts Crown Increased Takeover Bid\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-21 21:36</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Revance <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> has accepted a sweetened bid from Crown Laboratories that raises the purchase price to $3.65 a share from $3.10. \n</p>\n<p>\n  Revance on Tuesday said it signed a revised merger agreement with privately held Crown, which has extended its tender offer for the Nashville, Tenn., biotechnology company to Feb. 4. \n</p>\n<p>\n  Crown raised its offer for Revance after Swiss medical-aesthetics company Teoxane, a key Revance customer, stepped in with a bid of $3.60 a share. \n</p>\n<p>\n  Crown last year agreed to buy Revance for $6.66 a share but later reduced the purchase price in part due to new agreements that Revance reached with Teoxane to resolve claims that Revance has breached a 2020 distribution agreement. \n</p>\n<p>\n  Revance shares closed Friday at $3.68, an indication that some investors might be expecting a bidding war for the company. The shares slipped 0.9% to $3.65 in premarket trading Tuesday. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 21, 2025 08:36 ET (13:36 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2505730302","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505730302","pubTimestamp":1737466560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Revance Therapeutics has accepted a sweetened bid from Crown Laboratories that raises the purchase price to $3.65 a share from $3.10.Revance on Tuesday said it signed a revised merger agreement with privately held Crown, which has extended its tender offer for the Nashville, Tenn., biotechnology company to Feb. 4.Crown raised its offer for Revance after Swiss medical-aesthetics company Teoxane, a key Revance customer, stepped in with a bid of $3.60 a share.Crown last year agreed to buy Revance for $6.66 a share but later reduced the purchase price in part due to new agreements that Revance reached with Teoxane to resolve claims that Revance has breached a 2020 distribution agreement.Revance shares closed Friday at $3.68, an indication that some investors might be expecting a bidding war for the company. The shares slipped 0.9% to $3.65 in premarket trading Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","RVNC":"Revance Therapeutics Inc","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","BK4126":"金属与玻璃容器","LU1892829315.USD":"FIDELITY FUNDS SUSTAINABLE WATER & WASTE \"A\" (USD) ACC","CCK":"皇冠控股","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU1803068623.USD":"TEMPLETON GLOBAL CLIMATE CHANGE \"AH1\" (USDHDG) ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4007":"制药","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC"},"translate_title":"Revance Therapeutics接受皇冠提高的收购要约","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVNC":1,"CCK":1},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Revance Therapeutics has accepted a sweetened bid from Crown Laboratories that raises the purchase price to $3.65 a share from $3.10. \n\n\n  Revance on Tuesday said it signed a revised merger agreement with privately held Crown, which has extended its tender offer for the Nashville, Tenn., biotechnology company to Feb. 4. \n\n\n  Crown raised its offer for Revance after Swiss medical-aesthetics company Teoxane, a key Revance customer, stepped in with a bid of $3.60 a share. \n\n\n  Crown last year agreed to buy Revance for $6.66 a share but later reduced the purchase price in part due to new agreements that Revance reached with Teoxane to resolve claims that Revance has breached a 2020 distribution agreement. \n\n\n  Revance shares closed Friday at $3.68, an indication that some investors might be expecting a bidding war for the company. The shares slipped 0.9% to $3.65 in premarket trading Tuesday. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 21, 2025 08:36 ET (13:36 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}